Trials / Withdrawn
WithdrawnNCT01888562
Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma
A Pilot Evaluation of Ponatinib (AP24534), a Potent Oral Pan-FGFR Inhibitor, in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma: a Multi-Institutional Study
- Status
- Withdrawn
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To test the patient's cancerous tumor to see if it has a FGFR mutation and, if so, to see how their cancer responds to a treatment with the drug ponatinib as well as examine the side effects caused by ponatinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ponatinib | Ponatinib 45 mg daily for 4 weeks (4 weeks equal one cycle) |
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2018-07-01
- Completion
- 2023-07-01
- First posted
- 2013-06-27
- Last updated
- 2015-12-18
Source: ClinicalTrials.gov record NCT01888562. Inclusion in this directory is not an endorsement.